Market News & Trends
Sernova’s Clinical Trial Supported With Continuous Glucose Monitoring Systems
Sernova Corp. recently announced continuous glucose monitoring systems [CGM (Medtronic Minimed, Northridge, CA)] will be provided to patients in Sernova’s US regenerative medicine clinical trial…
Amunix Announces Licensing Agreement With Celgene
Amunix Operating Inc. recently announced it has entered into a licensing agreement with Celgene. The agreement allows for the utilization of Amunix’s proprietary XTEN and…
Novo Nordisk Successfully Completes Phase 3a Trial Using Emisphere's Technology
Novo Nordisk recently announced the successful completion of the first Phase 3a trial, PIONEER 1, with oral semaglutide, a once-daily oral formulation of the long-acting…
Biohaven Announces Exclusive License Agreement With Catalent
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") recently announced it has entered into an exclusive worldwide license agreement with Catalent U.K.…
Lonza Expands Encapsulation & HPAPI Capabilities in North America
Lonza recently announced the expansion of its late-stage clinical and commercial encapsulation capabilities for solid oral and inhaled dosage forms in North America. The company…
Shire Provides Regulatory Progress Update for Key Pipeline Programs Targeting Rare Disease
Shire plc recently announced the US FDA has granted Orphan Drug Designation to Shire's investigational therapy, SHP647, for the treatment of pediatric patients with moderately…
Regentys, Cook Biotech to Collaborate in Developing, Delivering Unique Ulcerative Colitis Treatment
Regentys recently announced it will partner with Cook Biotech Inc. to develop a novel treatment for ulcerative colitis. Under the terms of a signed letter…
Malvern Panalytical Launches New Morphologi 4 Range for Fast, High-Definition Particle Characterization Throughout Drug Development
The new Morphologi range of automated static imaging systems for particle characterization from Malvern Panalytical – Morphologi 4 and Morphologi 4-ID – has been unveiled.…
Horizon Discovery Enters License Agreement With US Immuno-Oncology Company
Horizon Discovery Group plc recently announced it has entered into a non-exclusive out-licensing agreement with a US-based immuno-oncology therapeutics developer (the Partner) for Horizon’s proprietary…
CordenPharma Announces Revamped Executive Leadership Team
CordenPharma is pleased to announce the appointments of Dr. Riku Heikki Rautsola as the new Chief Executive Officer & President, CordenPharma, Dr. Walter Kittl as…
Verona Pharma Provides Clinical Development Update
Verona Pharma plc recently announced updated projections, bringing forward the timing for top-line data readouts from its ongoing clinical trials in chronic obstructive pulmonary disease…
Majority of Oncology Clinical Trials in China Failed to Meet Enrolment Targets
The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the…
ERT Expands Respiratory Services to Support New Endpoints
ERT recently announced an advanced respiratory clinical trial service that centrally collects lung function data using the Forced Oscillation Technique (FOT). The service is available…
Xoc Pharmaceuticals Announces $30-Million Financing for Parkinson’s & Migraine
Xoc Pharmaceuticals, Inc. recently announced it has closed a tranched $30- million Series A financing led by global venture capital firm New Enterprise Associates (NEA).…
Vanrx Pharmasystems Announces Compatibility Between Ompi EZ-Fill Vials, Daikyo Seiko PLASCAP Press-Fit Closures & Aseptic Filling Workcells
Pharmapack Europe Expo – Vanrx announces that Ompi EZ-fill vials and Daikyo Seiko PLASCAP press-fit closures are confirmed as a Product Set for use with…
Rexahn Pharmaceuticals Announces Collaboration With Zhejiang Haichang Biotechnology
Rexahn Pharmaceuticals, Inc. recently announced it has entered into a collaboration and license agreement with Zhejiang Haichang Biotechnology Co., Ltd. (Haichang), to develop RX-0201 (Archexin)…
Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)
Madrigal Pharmaceuticals, Inc. recently announced positive results from a double-blind, placebo-controlled, multi-center, 12-week Phase 2 clinical trial in patients with heterozygous familial hypercholesterolemia (HeFH), a…
Akari Therapeutics Announces Completion of Phase II Trial
Akari Therapeutics, Plc recently announced additional data for its Phase II COBALT clinical trial and provides an update on other clinical trials with Coversin. The…
Biotech Merger & Acquisition Deal Activity Skyrockets in Early 2018
One month into 2018, biotech merger and acquisition (M&A) deal activity has already skyrocketed. Acquisitions from colossal drug makers, Celgene and Sanofi, total more than…
Merck Set to Lead Licensing Deals in 2018
The pharmaceutical industry is highly volatile, with promising lead candidates making or breaking a company’s year. Companies’ financial success is often down to the strategic…
